IONS in the 13F filings
Ionis Pharmaceuticals Inc · CUSIP 462222100
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 35
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 17 listed it in both
- Shares listed
- 67,438,108
- combined, among listed positions
- Reported value
- $5.3bn
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 20 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +4,838,240.
Managers listing IONS in Q4 2025
35 of 35 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 17,961,299 shares now+5,238,571
- Two Sigma Investments LPexisting position · 2,658,646 shares now+1,082,703
- Two Sigma Advisers LPexisting position · 3,052,111 shares now+979,000
- Invesco Ltdexisting position · 1,269,290 shares now+750,220
- Arrowstreet Capital LPexisting position · 1,063,327 shares now+433,191
Reductions
- Marshall Wace LLPexisting position · 256,933 shares now-701,896
- Millennium Management LLCexisting position · 93,262 shares now-686,308
- Balyasny Asset Management LLCexisting position · 120,577 shares now-639,534
- Susquehanna International Group LLPexisting position · 32,504 shares now-388,446
- Jane Street Group LLCexisting position · 30,471 shares now-334,599
New positions and exits
New (2)
Exited (2)
- Schonfeld Strategic Advisors LLCwas $13m
- Brevan Howard Capital Management LPwas $295k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2015 | 14 | $1.8bn | n.a. | n.a. |
| Q1 2016 | 7 | $1.1bn | n.a. | n.a. |
| Q2 2016 | 3 | $667m | n.a. | n.a. |
| Q3 2016 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2016 | 7 | $1.6bn | n.a. | n.a. |
| Q1 2017 | 5 | $1.4bn | n.a. | n.a. |
| Q2 2017 | 6 | $1.9bn | n.a. | n.a. |
| Q3 2017 | 6 | $1.9bn | n.a. | n.a. |
| Q4 2017 | 7 | $1.9bn | n.a. | n.a. |
| Q1 2018 | 7 | $1.6bn | n.a. | n.a. |
| Q2 2018 | 6 | $1.6bn | n.a. | n.a. |
| Q3 2018 | 8 | $2.1bn | n.a. | n.a. |
| Q4 2018 | 11 | $2.1bn | n.a. | n.a. |
| Q1 2019 | 14 | $3.5bn | n.a. | n.a. |
| Q2 2019 | 11 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 10 | $2.6bn | n.a. | n.a. |
| Q4 2019 | 10 | $2.5bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.1bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.6bn | n.a. | n.a. |
| Q3 2020 | 15 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 14 | $2.5bn | n.a. | n.a. |
| Q1 2021 | 9 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 10 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 8 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 9 | $1.3bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.6bn | n.a. | n.a. |
| Q2 2022 | 12 | $1.6bn | n.a. | n.a. |
| Q3 2022 | 11 | $1.5bn | n.a. | n.a. |
| Q4 2022 | 9 | $1.2bn | n.a. | n.a. |
| Q1 2023 | 7 | $1.0bn | n.a. | n.a. |
| Q2 2023 | 10 | $1.3bn | n.a. | n.a. |
| Q3 2023 | 12 | $1.4bn | n.a. | n.a. |
| Q4 2023 | 14 | $1.9bn | 10 | 4 |
| Q1 2024 | 15 | $1.7bn | 9 | 5 |
| Q2 2024 | 17 | $2.1bn | 12 | 5 |
| Q3 2024 | 16 | $2.1bn | 11 | 7 |
| Q4 2024 | 11 | $1.7bn | 7 | 5 |
| Q1 2025 | 10 | $1.5bn | 7 | 3 |
| Q2 2025 | 13 | $2.1bn | 8 | 5 |
| Q3 2025 | 18 | $3.6bn | 9 | 8 |
| Q4 2025 | 15 | $4.9bn | 15 | 20 |
| Q1 2026 | 16 | $5.0bn | 21 | 13 |
| Q2 2026 | 13 | $5.5bn | 13 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IONS and LLY →IONS and JNJ →IONS and VRTX →Choose a stock to compare with IONS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IONS, latest filings →Back to the 13F Explorer →